- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This handbook has been written by a group of patients in British Columbia. We all have long experience with medication-assisted treatments for opioid dependence. The language about drug use is complex. The latest version of the manual that defines diseases and disorders (DSM-V) no longer refers to “dependence” and uses “addiction” instead. In this handbook, we continue to use “dependence” to refer to our experience of “needing the drug” and significant withdrawal symptoms when trying to quit or cut down on our use. Deciding to seek help is an important step in any process of recovery. You are making a wise decision to seek help now. People dependent on opioid drugs and not receiving opioid substitution treatment (OST) are many times more likely to die or be seriously harmed by problem drug use.
This report presents background information on Kiribati, its health-care system and the national epidemiology of hepatitis. It then details review findings and recommendations under each priority area of action of the Regional Action Plan for Viral Hepatitis in the Western Pacific 2016–2020: broad-based advocacy and awareness, evidence-based policy guiding comprehensive hepatitis action, data supporting the hepatitis response, stopping transmission, and an accessible and effective treatment cascade.
Keywords: co-infection, transmission, treatment cascade, policy
With the 2016 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, WHO updated and launched new policy recommendations on the clinical and service delivery aspects of HIV treatment and care, and raised the bar to treat all PLHIV (Treat All). WHO has worked with countries to ensure uptake and implementation of these recommendations in support of the to the 90-90-90 targets.
This fact sheet present data for 194 WHO Member States – including 139 low- and middle-income countries – and 35 Fast-Track countries, respectively through November 2017.
This second HIVDR report provides an update on recent population levels of HIVDR covering the period 2014–2016. The report includes data from 16 nationally representative surveys from 14 countries estimating resistance in: adults initiating ART (PDR), children younger than 18 months newly diagnosed with HIV, and adults on ART (acquired HIV drug resistance or ADR).
To contextualize results from representative HIVDR surveys, the report is supported by systematic reviews of the published literature on PDR in adults, children and adolescents, and ADR in paediatric and adult populations.
Preventing and managing the emergence of HIVDR is a key component of a comprehensive and effective HIV response, and should be integrated into broader efforts to ensure sustainability and greatest impact. It is essential that actions to monitor, prevent and respond to HIVDR are implemented at the clinical, programme and policy levels to address the many drivers of HIVDR.
The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on health and HIV, and to provide the most effective treatment to all people living with HIV including adults, key populations, pregnant and breastfeeding women, children and adolescents.
The Action Plan (2016-2021) for addressing viral hepatitis in the WHO South-East Asia Region has been developed in consultation with Member States, community stakeholders, development partners, academia and professional societies. Drawing upon the Global Health Sector Strategy for Viral Hepatitis (2016–2021) and using the framework of universal health coverage to ensure that no one is left behind, the Action Plan provides a roadmap for priority areas of focus and interventions within the health and related sectors that are needed at the national level to mount an effective and efficient response to prevention, diagnosis, management and care of viral hepatitis.
This report provides in-depth technical discussions in areas that have direct implications to the containment of AMR as a development agenda. The report is organized in five chapters which served as the technical background documents for the Biregional Technical Consultation on AMR in Asia, 14-15 April 2016. More information from the meeting is available in the WHO Meeting Report: Biregional Technical Consultation on Antimicrobial Resistance in Asia. The meeting was the first time senior officials from the Ministry of Health and Ministry of Agriculture across Asia came together to tackle AMR.
Keywords: drug resistance, microbial, infection control
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillance of antimicrobial resistance in the foodborne bacteria (i.e., bacteria commonly transmitted by food) by taking a One Health approach. This guidance document replaces the previous version published in 2013.
Keywords: antimicrobial use, analysis, reporting, data
The world has embraced the UNAIDS 90–90–90 treatment target, whereby 90% of people living with HIV know their HIV status, 90% of people who know their HIV-positive status are accessing antiretroviral treatment, and 90% of people on treatment have suppressed viral loads. By reaching the 90–90–90 treatment target by 2020, the world will be firmly on track towards ending the AIDS epidemic by 2030.
Keywords: HIV, treatment, HLM2016AIDS, ART, Fast-Track
Data from the DOH - Epidemiology Bureau shows that only 44o/o of allpeople diagnosed with HIV from 2010 to 2015 were started on Anti-Retroviral Therapy (ART). Based on the 2013 external evaluation of the health sector's response to HIV in the Philippines, long turn-around time of confirmatory HIV testing is one of the identified barriers for prompt referral and management. In the interim, this memorandum shall ensure linkage to care of clients with reactive HIV screening test to immediately be assessed by Treatment hubs, satellite treatment hubs and HIV primary care clinics in order to provide early treatment and management.